Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

Rhea-AI Summary

Constellation Pharmaceuticals (Nasdaq: CNST) will participate in two virtual investor conferences. CEO Jigar Raythatha will present at the H.C. Wainwright Global Investment Conference on September 14 at 1:00 PM EDT, and at the Cantor Global Healthcare Conference on September 17 at 1:20 PM EDT. Live audio webcasts will be available on their Investor Relations website, with replays accessible for 30 days post-presentation. The company focuses on developing therapeutics that modulate gene expression, addressing serious medical needs in cancer treatment.

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in upcoming virtual investor conferences.  Jigar Raythatha, CEO, will present at:

• The H.C. Wainwright Global Investment Conference at 1:00 PM EDT on September 14
• The Cantor Global Healthcare Conference at 1:20 PM EDT on September 17 

Live audio webcasts of Mr. Raythatha’s presentations and archives for replay will be available on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events.  The audio webcast replays will be available for 30 days following the live presentation.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Contact

Kia Khaleghpour, Ph.D.
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1 617-844-6859
kia.khaleghpour@constellationpharma.com

Ronald Aldridge
Investor Relations
Constellation Pharmaceuticals
+1 617-714-0539
ron.aldridge@constellationpharma.com

Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060
larnold@macbiocom.com

FAQ

When will Constellation Pharmaceuticals present at the H.C. Wainwright Global Investment Conference?

Constellation Pharmaceuticals will present at the H.C. Wainwright Global Investment Conference on September 14 at 1:00 PM EDT.

What time is the Cantor Global Healthcare Conference presentation for Constellation Pharmaceuticals?

The presentation at the Cantor Global Healthcare Conference will take place on September 17 at 1:20 PM EDT.

How can I access the webcasts for Constellation Pharmaceuticals' investor presentations?

Live audio webcasts for the presentations can be accessed via the Investor Relations section of Constellation Pharmaceuticals' website.

What is the focus of Constellation Pharmaceuticals' research and development?

Constellation Pharmaceuticals focuses on developing therapeutics that modulate gene expression, specifically targeting cancer treatment.

What are the main therapeutic candidates being developed by Constellation Pharmaceuticals?

The main therapeutic candidates include the BET inhibitor CPI-0610 for myelofibrosis and the EZH2 inhibitor CPI-0209 for solid tumors.